Ferring Pharmaceuticals’ 1st in Class C.diff Treatment, Rebyota, Experiences a Positive Early Launch Ahead of Potential Competition, According to Spherix Global Insights

Aimmune/Seres’ SER-109 Poised to Challenge First to Market Ferring’s Rebyota for Treatment of Clostridioides Difficile EXTON, Pa., March 17, 2023 /PRNewswire/ — When the FDA approved Rebyota, a new class of Clostridioides Difficile (C.diff) treatment, Ferring Pharmaceuticals ushered in…

Click here to view original post